FOSTER CITY, Calif.--(BUSINESS WIRE)--Silicon Valley Biosystems (SV Bio) today announced that it has changed its name to Lifecode, Inc. The new name is consistent with the company’s mission of improving the lives of patients by providing concise, accurate and actionable molecular information. Lifecode has also announced that it has released its flagship next generation sequencing (NGS)-based oncology assay, the Pan Cancer Somatic Panel (PCSP), to a select group of physicians nationwide in advance of a broad launch later this spring.
Lifecode is developing a portfolio of NGS-based cancer assays, including the Pan Cancer Somatic Panel. Lifecode’s Laboratory Developed Tests (LDT’s) are developed exclusively on an NGS platform, utilizing a variety of machine learning techniques, proprietary algorithms, and custom annotation and curation tools to accurately detect and interpret genomic alterations in patient tumor samples.
The company’s intense focus on the rapid analysis, interpretation, and clinical reporting of complex sequencing information is unique to the clinical laboratory industry. The leadership team at Lifecode brings together extensive expertise in mathematics, data science, cancer biology and software development, helping to create novel engineering solutions for “big data” challenges in clinical genomics.
“As we move into this new era of personalized medicine in oncology, Lifecode will help to drive this transition using the most advanced tools in genome-guided medicine. Our goal is to provide accurate and actionable information for use in both near and long-term treatment decisions,” said Chris Rivest, CEO of Lifecode, Inc. “As NGS capabilities have improved, there has been an exponential increase the quantity of clinical and research data regarding the molecular basis of cancer. Our goal at Lifecode is to help physicians manage the flood of information by leveraging our world class computational tools, algorithms, and data science.”
With financial support from Sequoia Capital, the Mayo Clinic and Mayo Ventures, Lifecode has positioned itself to be a leader in the dynamic and rapidly evolving field of cancer genomics.
About Lifecode, Inc.
Lifecode is a specialized CLIA certified clinical laboratory focused on the genetic basis of human disease. With an initial focus on oncology, we are committed to improving the lives of patients through molecular information that is concise, accurate and actionable. The long-term vision of Lifecode is to revolutionize the world of genomic medicine: better care through better code. Lifecode is based in Foster City, California, in the heart of Silicon Valley.
